NAKA vs HIMS vs TDOC vs OPRX

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -33. 0% for Nakamoto Inc. (NAKA). OptimizeRx Corporation (OPRX) offers the better valuation at 19. 7x trailing P/E (5. 6x forward), making it the more compelling value choice. Analysts rate Nakamoto Inc. (NAKA) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, OptimizeRx Corporation (OPRX) is the cheapest at 19.

7x versus Hims & Hers Health, Inc. at 59. 2x.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +150. 0%, compared to -96. 3% for Nakamoto Inc. (NAKA). Over 10 years, the gap is even starker: HIMS returned +207. 9% versus NAKA's -96. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Teladoc Health, Inc.

(TDOC) is the lower-risk stock at 1. 85β versus Nakamoto Inc. 's 2. 88β — meaning NAKA is approximately 56% more volatile than TDOC relative to the S&P 500. On balance sheet safety, OptimizeRx Corporation (OPRX) carries a lower debt/equity ratio of 20% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -33. 0% for Nakamoto Inc. (NAKA). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to -1452. 2% for Nakamoto Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -28. 7% for Nakamoto Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OPRX leads at 11. 0% versus -108. 2% for NAKA. At the gross margin level — before operating expenses — HIMS leads at 73. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for OPRX: 219.

5% to $17. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hims & Hers Health, Inc.

(HIMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+207. 9% 10Y return). Nakamoto Inc. (NAKA) carries a higher beta of 2. 88 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HIMS: +207. 9%, NAKA: -96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NAKA (Financial Services) and HIMS (Healthcare) and TDOC (Healthcare) and OPRX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NAKA is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; TDOC is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.